August 04, 2022
1 min read
LumiThera has purchased the assets of MacuLogix through its wholly owned subsidiary, according to a press release.
MacuLogix developed the AdaptDx Pro dark adaptometer, a wearable device used to diagnose dry age-related macular degeneration. It launched in 2020.
“AdaptDx Pro can identify dry AMD patients at the earliest timepoint, in advance of pathology and before vision loss,” Clark E. Tedford, PhD, president and CEO of LumiThera, said in the release. “The AdaptDx wearable, light-based early diagnostic for dry AMD adds a complementary assessment of retinal health to the LumiThera product line, further expanding LumiThera’s synergistic platform of products for eye care professionals. We are excited to combine diagnosis, treatment and monitoring platforms to provide a complete solution for dry AMD patients.”
The AdaptDx device measures the inability to adapt to low light levels, an early sign of AMD. More than 1 million tests have been performed and 200,000 patients have been diagnosed with the device, according to Greg Jackson, PhD, former MacuLogix chief technology officer and co-founder.
Terms of the deal were not announced.
